Human CCL21 ELISA Kit
Key features and details
- Specification:
- Sensitivity:
- Standard Curve Range:
- Standard Curve Gradient:
- Number of Incubations:
- Sample Volume:
- Assay type:
- Operation Duration:
-
Brand:
CAT.NO. : AEH0184
RMB Please choose
RMB Please choose
Size:
Trail, Bulk size or Custom requests Please contact us
Product Details
Background
6Ckine is a novel CC chemokine discovered independently by three groups from the EST database. 6Ckine, also named SLC (secondary lymphoid-tissue chemokine), CCL21 and Exodus-2, shows 21-33% identity to other CC chemokines. 6Ckine contains the four conserved cysteines characteristic of beta chemokines plus two additional cysteines in its unusually long carboxyl-terminal domain. Human 6Ckine cDNA encodes a 134 amino acid residue, highly basic, precursor protein with a 23 amino acid residue signal peptide that is cleaved to form the predicted 111 amino acid residue mature protein. Mouse 6Ckine cDNA encodes a 133 amino acid residue protein with a 23 residue signal peptide that is cleaved to generate the 110 residue mature protein. Human and mouse 6Ckine are highly conserved, exhibiting 86% amino acid sequence identity. 6Ckine is constitutively expressed at high levels in lymphoid tissues such as lymph nodes, spleen and appendix. In mouse, high levels of 6Ckine mRNA are also detected in the lung. The gene for human 6Ckine has been localized at human chromosome 9p13 rather than chromosome 17 where the genes of many human CC chemokines are clustered. The 6Ckine gene location is within a region of about 100 kb from the MIP-3 beta /ELC gene, another identified novel CC chemokine. Unlike most CC chemokines, 6Ckine is not chemotactic for monocytes. 6Ckine has also been reported to inhibit hemopoietic progenitor colony formation in a dose-dependent manner. 6Ckine acts via a class of as yet unidentified CC receptors on both T cells and B cells that are not shared by any other CC chemokines. Mature rat CCL21 shares 84% aa sequence identity with mouse CCL21.
Typical data
|
pg/ml |
O.D. |
Average |
Corrected |
|
|
0.00 |
0.0074 |
0.0067 |
0.0071 |
|
|
78.13 |
0.0120 |
0.0117 |
0.0119 |
0.0048 |
|
156.25 |
0.0224 |
0.0216 |
0.0220 |
0.0150 |
|
312.50 |
0.0676 |
0.0607 |
0.0642 |
0.0571 |
|
625.00 |
0.2375 |
0.2112 |
0.2244 |
0.2173 |
|
1250.00 |
0.7413 |
0.6874 |
0.7144 |
0.7073 |
|
2500.00 |
2.2300 |
2.1320 |
2.1810 |
2.1740 |
|
5000.00 |
4.3823 |
4.3740 |
4.3782 |
4.3711 |
Precision
|
Intra-assay Precision |
Inter-assay Precision |
|||||
|
Sample Number |
S1 |
S2 |
S3 |
S1 |
S2 |
S3 |
|
22 |
22 |
22 |
6 |
6 |
6 |
|
|
Average(pg/ml) |
147.8 |
636.1 |
1906.2 |
141.4 |
622.2 |
1920.8 |
|
Standard Deviation |
4.8 |
11.4 |
59.7 |
4.5 |
18.5 |
79.0 |
|
Coefficient of Variation(%) |
3.2 |
1.8 |
3.1 |
3.2 |
3.0 |
4.1 |
Inter-assay Precision (Precision between assays) Three samples of known concentration were tested six times on one plate to assess intra-assay precision.
Spike Recovery
The spike recovery was evaluated by spiking 3 levels of human CCL21 into health human serum sample. The un-spiked serum was used as blank in this experiment.
The recovery ranged from 78% to 113% with an overall mean recovery of 86%.
The recovery ranged from 78% to 113% with an overall mean recovery of 86%.
Sample Values
| Sample Matrix | Sample Evaluated | Range (pg/ml) | Detectable (%) | Mean of Detectable (pg/ml) |
|---|---|---|---|---|
| Serum | 30 | 168-575.39 | 100 | 312.47 |
Serum/Plasma – Thirty samples from apparently healthy volunteers were evaluated for the presence of CCL21 in this assay. No medical histories were available for the donors.
New Products
